NCT00582140View on ClinicalTrials.gov

Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

pTVG-HP with rhGM-CSF

pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses

BIOLOGICAL

pTVG-HP with rhGM-CSF

pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses

BIOLOGICAL

pTVG-HP with rhGM-CSF

pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses

Trial Locations (1)

53792

University of Wisconsin, Madison

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Wisconsin, Madison

OTHER

NCT00582140 - Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter